Omeros (NASDAQ:OMER) Stock Rating Upgraded by StockNews.com

Omeros (NASDAQ:OMERGet Free Report) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

Omeros Price Performance

Shares of OMER stock opened at $3.05 on Wednesday. The stock has a market cap of $191.75 million, a P/E ratio of 9.53 and a beta of 1.34. The company has a fifty day moving average price of $3.87 and a two-hundred day moving average price of $2.97. Omeros has a one year low of $0.92 and a one year high of $7.80.

Hedge Funds Weigh In On Omeros

Large investors have recently modified their holdings of the stock. Barclays PLC raised its position in shares of Omeros by 51.2% in the third quarter. Barclays PLC now owns 45,629 shares of the biopharmaceutical company’s stock valued at $134,000 after purchasing an additional 15,456 shares during the period. Farther Finance Advisors LLC bought a new position in Omeros during the second quarter worth about $33,000. SG Americas Securities LLC bought a new position in Omeros during the third quarter worth about $56,000. Ancora Advisors LLC increased its position in Omeros by 23.1% during the third quarter. Ancora Advisors LLC now owns 210,023 shares of the biopharmaceutical company’s stock worth $613,000 after acquiring an additional 39,475 shares during the period. Finally, Walleye Trading LLC bought a new position in Omeros during the third quarter worth about $50,000. 48.79% of the stock is owned by institutional investors.

About Omeros

(Get Free Report)

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.

Featured Articles

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.